Results 151 to 160 of about 801,899 (276)
Lifelong evolution of autoreactive plasma cell numbers, affinity and anatomical location in arthritic K/BxN mice
Arthritis &Rheumatology, Accepted Article.Objective
The spontaneous K/BxN mouse model of rheumatoid arthritis has been used extensively to study chronic inflammation, contribution of immune cells, and the primordial role of autoreactive antibodies in disease initiation and severity. Only the ubiquitous enzyme glucose‐6‐phosphate isomerase (GPI) is the target of IgG autoantibodies secreted by ...Thibault Vanhoucke, Carlos Castrillon, Odile Richard‐Le Goff, Angga Perima, Matteo Broketa, Andrew D. Griffiths, Patrick England, François Huetz, Pierre Bruhns +8 morewiley +1 more sourceRomosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis
Arthritis &Rheumatology, Accepted Article.Background
Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.Giovanni Adami, Francesco Pollastri, Angelo Fassio, Filippo Montanari, Anna Piccinelli, Camilla Benini, Emma Pasetto, Carmen Dartizio, Davide Gatti, Maurizio Rossini, Ombretta Viapiana +10 morewiley +1 more sourceEfficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study
Arthritis &Rheumatology, Accepted Article.Objective
The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods
Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, The TULIP‐SC investigators +12 morewiley +1 more sourceGlucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases
Arthritis &Rheumatology, Accepted Article.Objective
GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta +4 morewiley +1 more sourceMeasuring the Impact: MRI Response of Sacroiliac Joints to TNF Inhibitors in Youth with Axial Disease
Arthritis &Rheumatology, Accepted Article.Objective
To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes in youth with axial juvenile spondyloarthritis (axJSpA) initiating TNF inhibitor (TNFi).Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss +8 morewiley +1 more sourceMethodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024-2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms. [PDF]
AllergyBousquet J, Sousa-Pinto B, Vieira RJ, Schünemann HJ, Zuberbier T, Bognanni A, Togias A, Samolinski B, Valiulis A, Williams S, Bedbrook A, Czarlewski W, Torres MJ, Shamji MH, Morais-Almeida M, Canonica GW, Vecillas LL, Dykewicz MS, Jacomelli C, Klimek L, Leemann L, Lourenço O, Palamarchuk Y, Papadopoulos NG, Pereira AM, Savouré M, Toppila-Salmi SK, Ventura MT, Yepes-Nuñez JJ, Cruz AA, Ciprandi G, Gemicioglu B, Giovannini M, Gradauskiene B, Jartti T, Jeseňák M, Kuna P, Kvedariene V, Larenas-Linnemann DE, Latiff AHA, Mohammad Y, Ohta K, Mahesh PA, Pali-Schöll I, Pfaar O, Regateiro FS, Roche N, Sofiev M, Taborda-Barata L, Ulrik CS, Rostan MV, Viegi G, Zhang L, Antó JM, Haahtela T, Cherrez-Ojeda I, Ivancevich JC, Khaltaev N, Yorgancioglu A, Abdullah B, Al-Ahmad M, Al-Nesf MA, Amaral R, Asllani J, Bergmann KC, Bernstein JA, Blaiss MS, Braido F, Camargos P, Carreiro-Martins P, Casale T, Cecchi L, Fiocchi AG, Giuliano AFM, Christoff G, Cirule I, Correia-de-Sousa J, Costa EM, Del Giacco S, Devillier P, Dokic D, Hossny E, Iinuma T, Irani C, Ispayeva Z, Julge K, Kaidashev I, Bennoor KS, Kraxner H, Kull I, Kulus M, Kupczyk M, Kurchenko A, La Grutta S, Miculinic N, Tuyet LLT, Makris M, Milenkovic B, Lee SM, Montefort S, Moreira A, Mullol J, Nadif R, Nakonechna A, Neffen HE, Niedoszytko M, Nyembue D, O'Hehir R, Ogulur I, Okamoto Y, Olze H, Palomares O, Panzner P, Patella V, Pawankar R, Pitsios C, Popov TA, Puggioni F, Quirce S, Ramonaité A, Recto M, Repka-Ramirez MS, Roberts G, Robles-Velasco K, Rottem M, Salapatas M, Sastre J, Scichilone N, Sisul JC, Solé D, Soto-Martinez ME, Sova M, Tantilipikorn P, Todo-Bom A, Tsaryk V, Tsiligianni I, Urrutia-Pereira M, Valovirta E, Van Ganse E, Vasankari T, Wallace D, Wang Y, Worm M, Yusuf OM, Zidarn M, Gil-Mata S, Marques-Cruz M, Mahboub B, Ansotegui IJ, Romano A, Artesani MC, Barreto B, Becker S, Beghe B, Bouchard J, Bourgoin-Heck M, Brussino L, Buhl R, Calvo-Gil M, Dahl VC, Vizuete JAC, Charpin D, Chavannes NH, Chełmińska M, Cheng L, Chkhartishvili E, Chong-Neto HJ, Choudhury D, Chu D, Cingi C, Compalati E, Cvetkovski B, Da Silva J, D'Amato G, Davies J, Di Bona D, Dimou MV, Teixeira MDC, Doulaptsi M, Pérez JMF, Gawlik R, Goksel O, Gómez MR, Gonzalez Diaz SN, Gotua M, Grigoreas C, Grisle I, Guzman MA, Tan RH, Hyland M, Ierodiakonou D, Karavelia A, Kisiel M, Kosnik M, Kritikos V, Lombardi C, Martini M, Meço C, Mesonjesi E, Mihaltan F, Moniuszko M, Naclerio R, Neisinger S, Ordak M, Paoletti G, Perdomo-Flores EA, Pham-Thi N, Prokopakis E, Yeverino DR, Rolla G, Romantowski J, Rouadi PW, Rukhadze M, Sakurai D, Salameh L, Sarquis FS, Kosak TS, Soyka M, Sozinova O, Specjalski K, Tomic-Spiric V, Vachova M, van Hage M, Koyuncu IV, Vichyanond P, Wagenmann M, Ko FWS, Werminghaus P, Xepapadaki VP, Xiang YK, Fonseca JA. +230 moreeuropepmc +1 more source
